Molly O'REilly
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Molly O'REilly has a total of 135 co-authors. Here are the top co-authors by number of shared publications:
- Larissa Fabritz
Department of Cardiology, University Heart & Vascular Centre Hamburg, University Medical Centre Hamburg-Eppendorf , Hamburg
7 shared publications - Laura Charlotte Sommerfeld
University Center of Cardiovascular Science (UCCS), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany
7 shared publications - Paulus Kirchhof
Institute of Cardiovascular Sciences, University of Birmingham, Birmingham B15 2TT, UK
6 shared publications - S. Nashitha Kabir
Department of Physiology, Anatomy & Genetics, University of Oxford , Oxford
6 shared publications - Katja Gehmlich
Institute of Cardiovascular Sciences, University of Birmingham, Birmingham B15 2TT, UK
5 shared publications - Christopher O'SHea
Department of Cardiovascular Sciences, College of Medicine and Health, University of Birmingham , Birmingham B15 2TT
4 shared publications
Latest Publications
- Open Access
- 28 September 2026
- Published by Wiley in The Journal of Physiology
Neurocardiac crosstalk in inherited cardiac arrhythmias and cardiomyopathy
Inherited cardiac conditions are a leading cause of sudden cardiac death in young and otherwise healthy patients. They result from mutations in genes that encode proteins with various physiological functions. Despite knowledge of the underlying genetic basis, the disorders remain incompletely understood. There is significant interindividual variability in disease expression amongst patients, and incomplete penetrance amongst mutation carriers, indicating a more complex basis to these disorders. This review first discusses the well‐established role of the autonomic nervous system (ANS) in acquired cardiac conditions, and subsequently focuses on several classically considered ‘cardiac’ conditions in which the ANS is known to play an important role: the inherited channelopathies catecholaminergic polymorphic ventricular tachycardia (CPVT), Brugada syndrome (BrS) and long QT syndrome type 3 (LQT3), as well as an inherited arrhythmogenic cardiomyopathy (ACM). Despite each condition being caused by different genetic mutations, they share a fundamental commonality in that cardiac‐modulating neurons (e.g. those of the stellate and intracardiac ganglia) have recently been shown to be affected in addition to cardiomyocytes. Through closer examination of the pathophysiological contribution of a dysfunctional ANS to these conditions, novel avenues for both risk stratification and treatment design are likely to emerge. image
- 28 September 2026
- Published by Wiley in The Journal of Physiology
Open AccessNeurocardiac crosstalk in inherited cardiac arrhythmias and cardiomyopathy
Inherited cardiac conditions are a leading cause of sudden cardiac death in young and otherwise healthy patients. They result from mutations in genes that encode proteins with various physiological functions. Despite knowledge of the underlying genetic basis, the disorders remain incompletely understood. There is significant interindividual variability in disease expression amongst patients, and incomplete penetrance amongst mutation carriers, indicating a more complex basis to these disorders. This review first discusses the well‐established role of the autonomic nervous system (ANS) in acquired cardiac conditions, and subsequently focuses on several classically considered ‘cardiac’ conditions in which the ANS is known to play an important role: the inherited channelopathies catecholaminergic polymorphic ventricular tachycardia (CPVT), Brugada syndrome (BrS) and long QT syndrome type 3 (LQT3), as well as an inherited arrhythmogenic cardiomyopathy (ACM). Despite each condition being caused by different genetic mutations, they share a fundamental commonality in that cardiac‐modulating neurons (e.g. those of the stellate and intracardiac ganglia) have recently been shown to be affected in addition to cardiomyocytes. Through closer examination of the pathophysiological contribution of a dysfunctional ANS to these conditions, novel avenues for both risk stratification and treatment design are likely to emerge. image
- Open Access
- 21 March 2025
- Published by Elsevier in Journal of Molecular and Cellular Cardiology Plus
- Vol. 12, 100293
Electrophysiological comparison of left versus right stellate ganglia neurons
- 21 March 2025
- Published by Elsevier in Journal of Molecular and Cellular Cardiology Plus
- Vol. 12, 100293
Open AccessElectrophysiological comparison of left versus right stellate ganglia neurons
- Open Access
Redefining catecholaminergic polymorphic ventricular tachycardia (CPVT) as a neurocardiac condition
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmia syndrome characterised by adrenergic activity-induced sudden cardiac death. It is most often caused by mutations in the RYR2 gene encoding ryanodine receptor 2 (RyR2), which is essential for intracellular calcium handling. Research has traditionally focused on the consequences of mutations at the cardiomyocyte level. However, RyR2 is also expressed in neuronal tissue, and patients often present with clinical signs of autonomic dysfunction. Here, we assessed if there is a neuronal phenotype in this classically cardiac condition. Using the established CPVT mouse model Ryr2 -R2474S, we found that RyR2 is abundantly expressed in stellate ganglia neurons (SGNs) - the adrenergic neurons that project directly to the myocardium and modulate heart function. We revealed that in isolated Ryr2 -R2474S SGNs there is altered calcium homeostasis suggestive of intracellular calcium leakage, and increased neurite projections when maintained in culture. We furthermore showed that hearts of Ryr2 -R2474S mice are sympathetically hyper-innervated, with an increased heterogeneity in innervation within the myocardium. This led to changes in the quantities of neurotransmitters and their metabolites within the heart, indicating increased norepinephrine turnover. CPVT may therefore be redefined as a neurocardiac disorder, with neuronal dysregulation being a prominent component of the disease. In addition to cardiomyocytes, RYR2 mutations also affect stellate ganglia neuron function and cardiac innervation, with potential implications for arrhythmogenesis, risk stratification and therapy. Graphical In wildtype hearts, activation of sympathetic neurons leads to their release of norepinephrine (NE), which binds to beta adrenergic receptors (β-ARs) on the cardiomyocyte membrane. The resultant initiation of intracellular signalling cascades involving cyclic AMP (cAMP) leads to reduced inhibition of the sarcoendoplasmic reticulum (SR) calcium ATPase (SERCA) pump and consequent calcium overload in the SR. This triggers the opening of ryanodine receptor 2 (RyR2), causing SR calcium to be released into the cytoplasmic space resulting in a calcium wave which triggers contraction. In CPVT hearts, there is increased sympathetic neuron innervation of the ventricular myocardium. When cardiac sympathetic nerves are activated, there is an enhanced release of NE. This excess NE causes increased activation of β-ARs and an augmented intracellular cAMP response, which in turn leads to a greater reduction of the inhibition of SERCA, augmented SR calcium overload, and a heightened propensity for spontaneous calcium leakage to trigger a calcium wave, delayed afterdepolarisations, and arrhythmias. Figure created with BioRender.com .
Open AccessRedefining catecholaminergic polymorphic ventricular tachycardia (CPVT) as a neurocardiac condition
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmia syndrome characterised by adrenergic activity-induced sudden cardiac death. It is most often caused by mutations in the RYR2 gene encoding ryanodine receptor 2 (RyR2), which is essential for intracellular calcium handling. Research has traditionally focused on the consequences of mutations at the cardiomyocyte level. However, RyR2 is also expressed in neuronal tissue, and patients often present with clinical signs of autonomic dysfunction. Here, we assessed if there is a neuronal phenotype in this classically cardiac condition. Using the established CPVT mouse model Ryr2 -R2474S, we found that RyR2 is abundantly expressed in stellate ganglia neurons (SGNs) - the adrenergic neurons that project directly to the myocardium and modulate heart function. We revealed that in isolated Ryr2 -R2474S SGNs there is altered calcium homeostasis suggestive of intracellular calcium leakage, and increased neurite projections when maintained in culture. We furthermore showed that hearts of Ryr2 -R2474S mice are sympathetically hyper-innervated, with an increased heterogeneity in innervation within the myocardium. This led to changes in the quantities of neurotransmitters and their metabolites within the heart, indicating increased norepinephrine turnover. CPVT may therefore be redefined as a neurocardiac disorder, with neuronal dysregulation being a prominent component of the disease. In addition to cardiomyocytes, RYR2 mutations also affect stellate ganglia neuron function and cardiac innervation, with potential implications for arrhythmogenesis, risk stratification and therapy. Graphical In wildtype hearts, activation of sympathetic neurons leads to their release of norepinephrine (NE), which binds to beta adrenergic receptors (β-ARs) on the cardiomyocyte membrane. The resultant initiation of intracellular signalling cascades involving cyclic AMP (cAMP) leads to reduced inhibition of the sarcoendoplasmic reticulum (SR) calcium ATPase (SERCA) pump and consequent calcium overload in the SR. This triggers the opening of ryanodine receptor 2 (RyR2), causing SR calcium to be released into the cytoplasmic space resulting in a calcium wave which triggers contraction. In CPVT hearts, there is increased sympathetic neuron innervation of the ventricular myocardium. When cardiac sympathetic nerves are activated, there is an enhanced release of NE. This excess NE causes increased activation of β-ARs and an augmented intracellular cAMP response, which in turn leads to a greater reduction of the inhibition of SERCA, augmented SR calcium overload, and a heightened propensity for spontaneous calcium leakage to trigger a calcium wave, delayed afterdepolarisations, and arrhythmias. Figure created with BioRender.com .
- Open Access
Electrophysiological comparison of left versus right stellate ganglia neurons
Background: The stellate ganglia of the peripheral autonomic nervous system innervate the heart and continuously fine-tune cardiac function to meet physiological demands. The right stellate ganglion (RSG) predominantly innervates the sinoatrial node and has functional effects on chronotropy/heart rate, whereas the left stellate ganglion (LSG) has predominance in the ventricular myocardium and impacts inotropy/contractility. Whilst the innervation patterns and functional consequences of block and stimulation are well-documented, basic electrophysiological characterisation and single-cell comparison of RSG and LSG neurons has not been performed. In addition, sex differences in stellate ganglion action potential (AP) parameters may exist, but remain as yet unknown. Methods/Results: Here we characterise the electrical properties of enzymatically isolated mouse stellate ganglia neurons using the patch clamp technique. Using 500 ms depolarising pulses of varying amplitude, we provide detailed characterisation of basic AP properties and their correlations. We reveal that there are two populations of neurons in terms of their AP firing properties (phasic or tonic firing), with the majority (67%) firing with a phasic pattern. When all recordings were pooled, tonic neurons had a significantly larger AP amplitude (85 ± 3.0 vs 76 ± 2.4 mV) and overshoot (28 ± 1.8 vs 19 ± 1.8 mV) compared to phasic neurons (Prest ; -60 ± 1.5 vs -54 ± 1.3 mV, Prest of RSG vs LSG neurons, and in the MDP of male vs female neurons. However, all other AP parameters were similar. This suggests that the LSG and RSG can be combined irrespective of sex when investigating the electrophysiological properties of these distinct anatomical structures in healthy and disease conditions.
Open AccessElectrophysiological comparison of left versus right stellate ganglia neurons
Background: The stellate ganglia of the peripheral autonomic nervous system innervate the heart and continuously fine-tune cardiac function to meet physiological demands. The right stellate ganglion (RSG) predominantly innervates the sinoatrial node and has functional effects on chronotropy/heart rate, whereas the left stellate ganglion (LSG) has predominance in the ventricular myocardium and impacts inotropy/contractility. Whilst the innervation patterns and functional consequences of block and stimulation are well-documented, basic electrophysiological characterisation and single-cell comparison of RSG and LSG neurons has not been performed. In addition, sex differences in stellate ganglion action potential (AP) parameters may exist, but remain as yet unknown. Methods/Results: Here we characterise the electrical properties of enzymatically isolated mouse stellate ganglia neurons using the patch clamp technique. Using 500 ms depolarising pulses of varying amplitude, we provide detailed characterisation of basic AP properties and their correlations. We reveal that there are two populations of neurons in terms of their AP firing properties (phasic or tonic firing), with the majority (67%) firing with a phasic pattern. When all recordings were pooled, tonic neurons had a significantly larger AP amplitude (85 ± 3.0 vs 76 ± 2.4 mV) and overshoot (28 ± 1.8 vs 19 ± 1.8 mV) compared to phasic neurons (Prest ; -60 ± 1.5 vs -54 ± 1.3 mV, Prest of RSG vs LSG neurons, and in the MDP of male vs female neurons. However, all other AP parameters were similar. This suggests that the LSG and RSG can be combined irrespective of sex when investigating the electrophysiological properties of these distinct anatomical structures in healthy and disease conditions.
- Open Access
- 12 August 2024
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 120 (15) , 1907-1923
PITX2 deficiency leads to atrial mitochondrial dysfunction
Reduced left atrial PITX2 is associated with atrial cardiomyopathy and atrial fibrillation. PITX2 is restricted to left atrial cardiomyocytes in the adult heart. The links between PITX2 deficiency, atrial cardiomyopathy and atrial fibrillation are not fully understood. To identify mechanisms linking PITX2 deficiency to atrial fibrillation, we generated and characterized PITX2-deficient human atrial cardiomyocytes derived from human induced pluripotent stem cells (hiPSC) and their controls. PITX2-deficient hiPSC-derived atrial cardiomyocytes showed shorter and disorganised sarcomeres and increased mononucleation. Electron microscopy found an increased number of smaller mitochondria compared to the control. Mitochondrial protein expression was altered in PITX2-deficient hiPSC-derived atrial cardiomyocytes. Single-nuclear RNA-sequencing found differences in cellular respiration pathways and differentially expressed mitochondrial and ion channel genes in PITX2-deficient hiPSC-derived atrial cardiomyocytes. PITX2 repression in hiPSC-derived atrial cardiomyocytes replicated dysregulation of cellular respiration. Mitochondrial respiration was shifted to increased glycolysis in PITX2-deficient hiPSC-derived atrial cardiomyocytes. PITX2-deficient human hiPSC-derived atrial cardiomyocytes showed higher spontaneous beating rates. Action potential duration was more variable with an overall prolongation of early repolarization, consistent with metabolic defects. Gene expression analyses confirmed changes in mitochondrial genes in left atria from 42 patients with atrial fibrillation compared to 43 patients in sinus rhythm. Dysregulation of left atrial mitochondrial (COX7C) and metabolic (FOXO1) genes was associated with PITX2 expression in human left atria. In summary, PITX2 deficiency causes mitochondrial dysfunction and a metabolic shift to glycolysis in human atrial cardiomyocytes. PITX2-dependent metabolic changes can contribute to the structural and functional defects found in PITX2-deficient atria.
- 12 August 2024
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 120 (15) , 1907-1923
Open AccessPITX2 deficiency leads to atrial mitochondrial dysfunction
Reduced left atrial PITX2 is associated with atrial cardiomyopathy and atrial fibrillation. PITX2 is restricted to left atrial cardiomyocytes in the adult heart. The links between PITX2 deficiency, atrial cardiomyopathy and atrial fibrillation are not fully understood. To identify mechanisms linking PITX2 deficiency to atrial fibrillation, we generated and characterized PITX2-deficient human atrial cardiomyocytes derived from human induced pluripotent stem cells (hiPSC) and their controls. PITX2-deficient hiPSC-derived atrial cardiomyocytes showed shorter and disorganised sarcomeres and increased mononucleation. Electron microscopy found an increased number of smaller mitochondria compared to the control. Mitochondrial protein expression was altered in PITX2-deficient hiPSC-derived atrial cardiomyocytes. Single-nuclear RNA-sequencing found differences in cellular respiration pathways and differentially expressed mitochondrial and ion channel genes in PITX2-deficient hiPSC-derived atrial cardiomyocytes. PITX2 repression in hiPSC-derived atrial cardiomyocytes replicated dysregulation of cellular respiration. Mitochondrial respiration was shifted to increased glycolysis in PITX2-deficient hiPSC-derived atrial cardiomyocytes. PITX2-deficient human hiPSC-derived atrial cardiomyocytes showed higher spontaneous beating rates. Action potential duration was more variable with an overall prolongation of early repolarization, consistent with metabolic defects. Gene expression analyses confirmed changes in mitochondrial genes in left atria from 42 patients with atrial fibrillation compared to 43 patients in sinus rhythm. Dysregulation of left atrial mitochondrial (COX7C) and metabolic (FOXO1) genes was associated with PITX2 expression in human left atria. In summary, PITX2 deficiency causes mitochondrial dysfunction and a metabolic shift to glycolysis in human atrial cardiomyocytes. PITX2-dependent metabolic changes can contribute to the structural and functional defects found in PITX2-deficient atria.
- Open Access
- 29 May 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (6) , 1212
Chronic Mexiletine Administration Increases Sodium Current in Non-Diseased Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes
A sodium current (INa) reduction occurs in the setting of many acquired and inherited conditions and is associated with cardiac conduction slowing and increased arrhythmia risks. The sodium channel blocker mexiletine has been shown to restore the trafficking of mutant sodium channels to the membrane. However, these studies were mostly performed in heterologous expression systems using high mexiletine concentrations. Moreover, the chronic effects on INa in a non-diseased cardiomyocyte environment remain unknown. In this paper, we investigated the chronic and acute effects of a therapeutic dose of mexiletine on INa and the action potential (AP) characteristics in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) of a healthy individual. Control hiPSC-CMs were incubated for 48 h with 10 µM mexiletine or vehicle. Following the wash-out of mexiletine, patch clamp analysis and immunocytochemistry experiments were performed. The incubation of hiPSC-CMs for 48 h with mexiletine (followed by wash-out) induced a significant increase in peak INa of ~75%, without any significant change in the voltage dependence of (in)activation. This was accompanied by a significant increase in AP upstroke velocity, without changes in other AP parameters. The immunocytochemistry experiments showed a significant increase in membrane Nav1.5 fluorescence following a 48 h incubation with mexiletine. The acute re-exposure of hiPSC-CMs to 10 µM mexiletine resulted in a small but significant increase in AP duration, without changes in AP upstroke velocity, peak INa density, or the INa voltage dependence of (in)activation. Importantly, the increase in the peak INa density and resulting AP upstroke velocity induced by chronic mexiletine incubation was not counteracted by the acute re-administration of the drug. In conclusion, the chronic administration of a clinically relevant concentration of mexiletine increases INa density in non-diseased hiPSC-CMs, likely by enhancing the membrane trafficking of sodium channels. Our findings identify mexiletine as a potential therapeutic strategy to enhance and/or restore INa and cardiac conduction.
- 29 May 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (6) , 1212
Open AccessChronic Mexiletine Administration Increases Sodium Current in Non-Diseased Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes
A sodium current (INa) reduction occurs in the setting of many acquired and inherited conditions and is associated with cardiac conduction slowing and increased arrhythmia risks. The sodium channel blocker mexiletine has been shown to restore the trafficking of mutant sodium channels to the membrane. However, these studies were mostly performed in heterologous expression systems using high mexiletine concentrations. Moreover, the chronic effects on INa in a non-diseased cardiomyocyte environment remain unknown. In this paper, we investigated the chronic and acute effects of a therapeutic dose of mexiletine on INa and the action potential (AP) characteristics in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) of a healthy individual. Control hiPSC-CMs were incubated for 48 h with 10 µM mexiletine or vehicle. Following the wash-out of mexiletine, patch clamp analysis and immunocytochemistry experiments were performed. The incubation of hiPSC-CMs for 48 h with mexiletine (followed by wash-out) induced a significant increase in peak INa of ~75%, without any significant change in the voltage dependence of (in)activation. This was accompanied by a significant increase in AP upstroke velocity, without changes in other AP parameters. The immunocytochemistry experiments showed a significant increase in membrane Nav1.5 fluorescence following a 48 h incubation with mexiletine. The acute re-exposure of hiPSC-CMs to 10 µM mexiletine resulted in a small but significant increase in AP duration, without changes in AP upstroke velocity, peak INa density, or the INa voltage dependence of (in)activation. Importantly, the increase in the peak INa density and resulting AP upstroke velocity induced by chronic mexiletine incubation was not counteracted by the acute re-administration of the drug. In conclusion, the chronic administration of a clinically relevant concentration of mexiletine increases INa density in non-diseased hiPSC-CMs, likely by enhancing the membrane trafficking of sodium channels. Our findings identify mexiletine as a potential therapeutic strategy to enhance and/or restore INa and cardiac conduction.
- Open Access
- 12 February 2024
- Published by Wiley in The Journal of Physiology
- Vol. 602 (18) , 4409-4436
Reduced plakoglobin increases the risk of sodium current defects and atrial conduction abnormalities in response to androgenic anabolic steroid abuse
Androgenic anabolic steroids (AAS) are commonly abused by young men. Male sex and increased AAS levels are associated with earlier and more severe manifestation of common cardiac conditions, such as atrial fibrillation, and rare ones, such as arrhythmogenic right ventricular cardiomyopathy (ARVC). Clinical observations suggest a potential atrial involvement in ARVC. Arrhythmogenic right ventricular cardiomyopathy is caused by desmosomal gene defects, including reduced plakoglobin expression. Here, we analysed clinical records from 146 ARVC patients to identify that ARVC is more common in males than females. Patients with ARVC also had an increased incidence of atrial arrhythmias and P wave changes. To study desmosomal vulnerability and the effects of AAS on the atria, young adult male mice, heterozygously deficient for plakoglobin (Plako+/−), and wild type (WT) littermates were chronically exposed to 5α‐dihydrotestosterone (DHT) or placebo. The DHT increased atrial expression of pro‐hypertrophic, fibrotic and inflammatory transcripts. In mice with reduced plakoglobin, DHT exaggerated P wave abnormalities, atrial conduction slowing, sodium current depletion, action potential amplitude reduction and the fall in action potential depolarization rate. Super‐resolution microscopy revealed a decrease in NaV1.5 membrane clustering in Plako+/− atrial cardiomyocytes after DHT exposure. In summary, AAS combined with plakoglobin deficiency cause pathological atrial electrical remodelling in young male hearts. Male sex is likely to increase the risk of atrial arrhythmia, particularly in those with desmosomal gene variants. This risk is likely to be exaggerated further by AAS use. image Key points: Androgenic male sex hormones, such as testosterone, might increase the risk of atrial fibrillation in patients with arrhythmogenic right ventricular cardiomyopathy (ARVC), which is often caused by desmosomal gene defects (e.g. reduced plakoglobin expression). In this study, we observed a significantly higher proportion of males who had ARVC compared with females, and atrial arrhythmias and P wave changes represented a common observation in advanced ARVC stages. In mice with reduced plakoglobin expression, chronic administration of 5α‐dihydrotestosterone led to P wave abnormalities, atrial conduction slowing, sodium current depletion and a decrease in membrane‐localized NaV1.5 clusters. 5α‐Dihydrotestosterone, therefore, represents a stimulus aggravating the pro‐arrhythmic phenotype in carriers of desmosomal mutations and can affect atrial electrical function.
- 12 February 2024
- Published by Wiley in The Journal of Physiology
- Vol. 602 (18) , 4409-4436
Open AccessReduced plakoglobin increases the risk of sodium current defects and atrial conduction abnormalities in response to androgenic anabolic steroid abuse
Androgenic anabolic steroids (AAS) are commonly abused by young men. Male sex and increased AAS levels are associated with earlier and more severe manifestation of common cardiac conditions, such as atrial fibrillation, and rare ones, such as arrhythmogenic right ventricular cardiomyopathy (ARVC). Clinical observations suggest a potential atrial involvement in ARVC. Arrhythmogenic right ventricular cardiomyopathy is caused by desmosomal gene defects, including reduced plakoglobin expression. Here, we analysed clinical records from 146 ARVC patients to identify that ARVC is more common in males than females. Patients with ARVC also had an increased incidence of atrial arrhythmias and P wave changes. To study desmosomal vulnerability and the effects of AAS on the atria, young adult male mice, heterozygously deficient for plakoglobin (Plako+/−), and wild type (WT) littermates were chronically exposed to 5α‐dihydrotestosterone (DHT) or placebo. The DHT increased atrial expression of pro‐hypertrophic, fibrotic and inflammatory transcripts. In mice with reduced plakoglobin, DHT exaggerated P wave abnormalities, atrial conduction slowing, sodium current depletion, action potential amplitude reduction and the fall in action potential depolarization rate. Super‐resolution microscopy revealed a decrease in NaV1.5 membrane clustering in Plako+/− atrial cardiomyocytes after DHT exposure. In summary, AAS combined with plakoglobin deficiency cause pathological atrial electrical remodelling in young male hearts. Male sex is likely to increase the risk of atrial arrhythmia, particularly in those with desmosomal gene variants. This risk is likely to be exaggerated further by AAS use. image Key points: Androgenic male sex hormones, such as testosterone, might increase the risk of atrial fibrillation in patients with arrhythmogenic right ventricular cardiomyopathy (ARVC), which is often caused by desmosomal gene defects (e.g. reduced plakoglobin expression). In this study, we observed a significantly higher proportion of males who had ARVC compared with females, and atrial arrhythmias and P wave changes represented a common observation in advanced ARVC stages. In mice with reduced plakoglobin expression, chronic administration of 5α‐dihydrotestosterone led to P wave abnormalities, atrial conduction slowing, sodium current depletion and a decrease in membrane‐localized NaV1.5 clusters. 5α‐Dihydrotestosterone, therefore, represents a stimulus aggravating the pro‐arrhythmic phenotype in carriers of desmosomal mutations and can affect atrial electrical function.
- Open Access
- 12 December 2022
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 25 (3) , 1152-1161
Familial atrial fibrillation mutation M1875T-SCN5A increases early sodium current and dampens the effect of flecainide
Atrial fibrillation (AF) is the most common cardiac arrhythmia. Pathogenic variants in genes encoding ion channels are associated with familial AF. The point mutation M1875T in the SCN5A gene, which encodes the α-subunit of the cardiac sodium channel Nav1.5, has been associated with increased atrial excitability and familial AF in patients. We designed a new murine model carrying the Scn5a-M1875T mutation enabling us to study the effects of the Nav1.5 mutation in detail in vivo and in vitro using patch clamp and microelectrode recording of atrial cardiomyocytes, optical mapping, electrocardiogram, echocardiography, gravimetry, histology, and biochemistry. Atrial cardiomyocytes from newly generated adult Scn5a-M1875T+/− mice showed a selective increase in the early (peak) cardiac sodium current, larger action potential amplitude, and a faster peak upstroke velocity. Conduction slowing caused by the sodium channel blocker flecainide was less pronounced in Scn5a-M1875T+/− compared to wildtype atria. Overt hypertrophy or heart failure in Scn5a-M1875T+/− mice could be excluded. The Scn5a-M1875T point mutation causes gain-of-function of the cardiac sodium channel. Our results suggest increased atrial peak sodium current as a potential trigger for increased atrial excitability.
- 12 December 2022
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 25 (3) , 1152-1161
Open AccessFamilial atrial fibrillation mutation M1875T-SCN5A increases early sodium current and dampens the effect of flecainide
Atrial fibrillation (AF) is the most common cardiac arrhythmia. Pathogenic variants in genes encoding ion channels are associated with familial AF. The point mutation M1875T in the SCN5A gene, which encodes the α-subunit of the cardiac sodium channel Nav1.5, has been associated with increased atrial excitability and familial AF in patients. We designed a new murine model carrying the Scn5a-M1875T mutation enabling us to study the effects of the Nav1.5 mutation in detail in vivo and in vitro using patch clamp and microelectrode recording of atrial cardiomyocytes, optical mapping, electrocardiogram, echocardiography, gravimetry, histology, and biochemistry. Atrial cardiomyocytes from newly generated adult Scn5a-M1875T+/− mice showed a selective increase in the early (peak) cardiac sodium current, larger action potential amplitude, and a faster peak upstroke velocity. Conduction slowing caused by the sodium channel blocker flecainide was less pronounced in Scn5a-M1875T+/− compared to wildtype atria. Overt hypertrophy or heart failure in Scn5a-M1875T+/− mice could be excluded. The Scn5a-M1875T point mutation causes gain-of-function of the cardiac sodium channel. Our results suggest increased atrial peak sodium current as a potential trigger for increased atrial excitability.
- Open Access
Male sex hormone and reduced plakoglobin jointly impair atrial conduction and cardiac sodium currents
Androgenic anabolic steroids (AAS) are commonly abused by young men. Male sex associates with earlier manifestation of common and rare cardiac conditions including atrial fibrillation and arrhythmogenic right ventricular cardiomyopathy (ARVC). Clinical data suggest an atrial involvement in ARVC. The disease is caused by desmosomal gene defects such as reduced plakoglobin expression. Analysis of clinical records from 146 ARVC patients identified male preponderance and increased prevalence of atrial arrhythmias in patients with definite ARVC. Definite patients displayed ECG changes suggesting atrial remodelling. To study mechanisms of atrial remodelling due to desmosomal vulnerability and AAS, young adult male mice, heterozygously deficient for plakoglobin (Plako +/- ) and wildtype (WT) littermates, were chronically exposed to 5α-dihydrotestosterone (DHT) or placebo. DHT increased atrial expression of pro-hypertrophic, fibrotic and inflammatory transcripts. DHT caused atrial conduction slowing, decreased peak sodium current density, reduced action potential amplitude and lowered the peak depolarisation rate in Plako +/- but not WT atria. Super-resolution microscopy revealed a reduction in Na v 1.5 clustering in Plako +/- atrial cardiomyocytes following DHT exposure. These data reveal that AAS combined with plakoglobin deficiency cause pathological atrial electrical remodelling in young male hearts. AAS abuse may increase the risk of atrial myopathy in males with desmosomal gene variants.
Open AccessMale sex hormone and reduced plakoglobin jointly impair atrial conduction and cardiac sodium currents
Androgenic anabolic steroids (AAS) are commonly abused by young men. Male sex associates with earlier manifestation of common and rare cardiac conditions including atrial fibrillation and arrhythmogenic right ventricular cardiomyopathy (ARVC). Clinical data suggest an atrial involvement in ARVC. The disease is caused by desmosomal gene defects such as reduced plakoglobin expression. Analysis of clinical records from 146 ARVC patients identified male preponderance and increased prevalence of atrial arrhythmias in patients with definite ARVC. Definite patients displayed ECG changes suggesting atrial remodelling. To study mechanisms of atrial remodelling due to desmosomal vulnerability and AAS, young adult male mice, heterozygously deficient for plakoglobin (Plako +/- ) and wildtype (WT) littermates, were chronically exposed to 5α-dihydrotestosterone (DHT) or placebo. DHT increased atrial expression of pro-hypertrophic, fibrotic and inflammatory transcripts. DHT caused atrial conduction slowing, decreased peak sodium current density, reduced action potential amplitude and lowered the peak depolarisation rate in Plako +/- but not WT atria. Super-resolution microscopy revealed a reduction in Na v 1.5 clustering in Plako +/- atrial cardiomyocytes following DHT exposure. These data reveal that AAS combined with plakoglobin deficiency cause pathological atrial electrical remodelling in young male hearts. AAS abuse may increase the risk of atrial myopathy in males with desmosomal gene variants.
- Open Access
Increased early sodium current causes familial atrial fibrillation and dampens effect of flecainide
(1) Aims: Atrial fibrillation (AF) is the most common cardiac arrhythmia. Pathogenic variants in genes encoding ion channels are associated with familial AF. The point mutation M1875T in the SCN5A gene, which encodes the α-subunit of the cardiac sodium channel Na v 1.5, has been associated with increased atrial excitability and familial AF. (2) Methods: We designed a new murine model carrying the Scn5a -M1875T mutation enabling us to study the effects of the Na v 1.5 mutation in detail in vivo and in vitro using patch clamp and microelectrode recording of atrial cardiomyocytes, optical mapping, ECG, echocardiography, gravimetry, histology and biochemistry. (3) Results: Atrial cardiomyocytes from newly generated adult Scn5a -M1875T +/- mice showed a selective increase in the early (peak) cardiac sodium current, larger action potential amplitude and a faster peak upstroke velocity. Conduction slowing caused by the sodium channel blocker flecainide was less pronounced in Scn5a -M1875T +/- compared to wildtype atria. Overt hypertrophy or heart failure in Scn5a -M1875T +/- mice could be excluded. (4) Conclusion: The Scn5a -M1875T point mutation causes gain-of-function of the cardiac sodium channel. Our results suggest increased atrial peak sodium current as a potential trigger for increased atrial excitability and thus AF. What’s new: The point mutation M1875T in the C-terminal domain of the cardiac sodium channel Na v 1.5 causes an increase in early peak sodium current in left atria. The observed changes induced by this point mutation suggest an increase in peak sodium current as a cause of familial atrial fibrillation (AF). Our findings provide a possible explanation for the variable effectiveness of sodium channel blockers in patients with AF. Carriers of such sodium channel gain-of-function mutations may benefit more from tailored treatments. Graphical
Open AccessIncreased early sodium current causes familial atrial fibrillation and dampens effect of flecainide
(1) Aims: Atrial fibrillation (AF) is the most common cardiac arrhythmia. Pathogenic variants in genes encoding ion channels are associated with familial AF. The point mutation M1875T in the SCN5A gene, which encodes the α-subunit of the cardiac sodium channel Na v 1.5, has been associated with increased atrial excitability and familial AF. (2) Methods: We designed a new murine model carrying the Scn5a -M1875T mutation enabling us to study the effects of the Na v 1.5 mutation in detail in vivo and in vitro using patch clamp and microelectrode recording of atrial cardiomyocytes, optical mapping, ECG, echocardiography, gravimetry, histology and biochemistry. (3) Results: Atrial cardiomyocytes from newly generated adult Scn5a -M1875T +/- mice showed a selective increase in the early (peak) cardiac sodium current, larger action potential amplitude and a faster peak upstroke velocity. Conduction slowing caused by the sodium channel blocker flecainide was less pronounced in Scn5a -M1875T +/- compared to wildtype atria. Overt hypertrophy or heart failure in Scn5a -M1875T +/- mice could be excluded. (4) Conclusion: The Scn5a -M1875T point mutation causes gain-of-function of the cardiac sodium channel. Our results suggest increased atrial peak sodium current as a potential trigger for increased atrial excitability and thus AF. What’s new: The point mutation M1875T in the C-terminal domain of the cardiac sodium channel Na v 1.5 causes an increase in early peak sodium current in left atria. The observed changes induced by this point mutation suggest an increase in peak sodium current as a cause of familial atrial fibrillation (AF). Our findings provide a possible explanation for the variable effectiveness of sodium channel blockers in patients with AF. Carriers of such sodium channel gain-of-function mutations may benefit more from tailored treatments. Graphical